Teladoc Health, Inc. (NYSE:TDOC) Receives $9.50 Consensus PT from Brokerages

Teladoc Health, Inc. (NYSE:TDOC) has been given a consensus rating of “Hold” by the eighteen analysts that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, twelve have given a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year target price among analysts that have covered the stock in the last year is $9.50.

TDOC has been the subject of several analyst reports. Barclays started coverage on shares of Teladoc Health in a research report on Tuesday, December 9th. They set an “equal weight” rating and a $8.50 price target for the company. Bank of America decreased their target price on shares of Teladoc Health from $9.00 to $8.00 and set a “neutral” rating for the company in a research report on Tuesday, November 25th. BMO Capital Markets initiated coverage on shares of Teladoc Health in a report on Thursday, November 13th. They issued a “market perform” rating and a $8.00 price target on the stock. Citigroup decreased their price objective on Teladoc Health from $10.00 to $9.00 and set a “neutral” rating for the company in a report on Friday, January 9th. Finally, Evercore ISI dropped their target price on Teladoc Health from $9.00 to $8.00 and set an “in-line” rating on the stock in a research note on Thursday, October 30th.

Teladoc Health Price Performance

NYSE TDOC opened at $6.60 on Monday. The company has a market cap of $1.17 billion, a PE ratio of -5.15 and a beta of 2.04. The firm’s 50 day moving average price is $7.31 and its 200-day moving average price is $7.78. The company has a debt-to-equity ratio of 0.71, a quick ratio of 2.60 and a current ratio of 2.70. Teladoc Health has a 52-week low of $6.35 and a 52-week high of $15.21.

Teladoc Health (NYSE:TDOC) last announced its quarterly earnings results on Wednesday, October 29th. The health services provider reported ($0.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.05. The business had revenue of $626.44 million for the quarter, compared to the consensus estimate of $625.66 million. Teladoc Health had a negative return on equity of 10.59% and a negative net margin of 8.84%.The business’s revenue was down 2.2% compared to the same quarter last year. During the same period last year, the business posted ($0.19) EPS. Teladoc Health has set its Q4 2025 guidance at -0.250–0.100 EPS. Sell-side analysts forecast that Teladoc Health will post -1.16 EPS for the current fiscal year.

Insider Activity at Teladoc Health

In other Teladoc Health news, insider Fernando M. Rodrigues sold 4,209 shares of the firm’s stock in a transaction on Wednesday, December 3rd. The shares were sold at an average price of $7.48, for a total value of $31,483.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Charles Divita III sold 17,138 shares of the company’s stock in a transaction on Thursday, December 11th. The shares were sold at an average price of $7.63, for a total value of $130,762.94. Following the completion of the transaction, the chief executive officer directly owned 201,036 shares in the company, valued at approximately $1,533,904.68. The trade was a 7.86% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 33,288 shares of company stock worth $251,684. Corporate insiders own 0.58% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its stake in shares of Teladoc Health by 4.2% in the 3rd quarter. Vanguard Group Inc. now owns 21,910,950 shares of the health services provider’s stock valued at $169,372,000 after purchasing an additional 891,732 shares during the period. Dimensional Fund Advisors LP increased its holdings in Teladoc Health by 23.8% in the third quarter. Dimensional Fund Advisors LP now owns 6,889,194 shares of the health services provider’s stock valued at $53,260,000 after buying an additional 1,325,106 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Teladoc Health by 2.1% in the second quarter. Geode Capital Management LLC now owns 4,150,197 shares of the health services provider’s stock worth $36,153,000 after acquiring an additional 84,356 shares during the period. Ameriprise Financial Inc. boosted its stake in shares of Teladoc Health by 11.1% during the 3rd quarter. Ameriprise Financial Inc. now owns 2,284,697 shares of the health services provider’s stock worth $17,661,000 after acquiring an additional 227,385 shares in the last quarter. Finally, Allianz Asset Management GmbH grew its position in shares of Teladoc Health by 189.2% during the 3rd quarter. Allianz Asset Management GmbH now owns 1,619,391 shares of the health services provider’s stock valued at $12,518,000 after acquiring an additional 1,059,458 shares during the period. 76.82% of the stock is currently owned by hedge funds and other institutional investors.

About Teladoc Health

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.